Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
The chart shows the growth of an initial investment of $10,000 in The Cigna Group, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
The Cigna Group (CI) has returned -2.40% so far this year and -14.97% over the past 12 months. Looking at the last ten years, CI has achieved an annualized return of 7.02%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of The Cigna Group (CI) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.92% | 6.52% | -7.67% | 1.30% | ||||||||
| 2025 | 5.52% | 5.73% | 6.78% | 2.86% | -6.79% | 4.75% | -19.44% | 11.64% | -4.32% | -15.13% | 14.23% | -0.66% |
| 2024 | -0.11% | 10.71% | 8.09% | -1.56% | -1.53% | -2.95% | 5.47% | 7.68% | -4.37% | -9.01% | 7.82% | -17.86% |
| 2023 | -3.27% | -7.27% | -11.56% | -2.48% | -2.32% | 12.75% | 5.79% | -6.60% | 2.97% | 8.22% | -14.58% | 13.45% |
| 2022 | 0.42% | 3.63% | 1.06% | 1.89% | 8.53% | -2.86% | 4.40% | 3.46% | -2.59% | 15.07% | 1.76% | 0.83% |
| 2021 | 3.78% | -3.76% | 13.83% | 2.75% | 3.33% | -8.84% | -3.71% | -7.98% | -5.97% | 6.27% | -10.25% | 17.48% |
| 2020 | -6.33% | -5.61% | -3.40% | 15.35% | 2.77% | -4.47% | -8.12% | 2.00% | -3.74% | -1.41% | 23.10% | -2.51% |
| 2019 | 6.46% | -10.54% | -8.63% | -2.32% | -6.86% | 6.73% | 6.92% | -9.45% | -0.67% | 16.67% | 11.56% | 2.29% |
| 2018 | 2.06% | -5.51% | -14.16% | 1.76% | -1.53% | -0.15% | 5.87% | 4.70% | 11.07% | 2.19% | 2.00% | -15.52% |
| 2017 | 9.19% | 1.29% | -2.34% | 6.59% | 2.90% | 3.46% | 3.14% | 4.63% | 2.33% | 5.07% | 6.83% | -4.03% |
| 2016 | 1.33% | -7.99% | 0.28% | 0.49% | -0.38% | 1.35% | -8.45% | 12.71% | -0.58% |
The charts below present risk-adjusted performance metrics for The Cigna Group (CI) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CI compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current The Cigna Group volatility is 1.73%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 157.92B | 152.76B | 143.93B | 154.89B | 155.45B | 155.77B | 153.23B | 61.75B | 59.36B | 57.09B | 55.90B | 54.34B | 53.73B | 51.05B | 43.01B |
| Temporary Equity (USD) | - | 107.00M | 66.00M | 54.00M | 58.00M | 35.00M | 37.00M | 49.00M | 58.00M | 69.00M | 90.00M | 96.00M | 114.00M | - | - |
| Equity Attributable To Parent (USD) | 41.71B | 46.22B | 44.87B | 47.11B | 50.32B | 45.34B | 41.03B | 13.74B | 13.72B | 12.04B | 10.77B | 10.57B | 9.77B | 8.34B | 5.42B |
| Equity Attributable To Noncontrolling Interest (USD) | 161.00M | 21.00M | 13.00M | 18.00M | 7.00M | 6.00M | 7.00M | - | 4.00M | 9.00M | 15.00M | 14.00M | - | - | 12.00M |
| Equity (USD) | 41.87B | 46.24B | 44.89B | 47.13B | 50.33B | 45.34B | 41.04B | 13.74B | 13.73B | 12.04B | 10.79B | 10.58B | 9.77B | 8.34B | 5.43B |
| Redeemable Noncontrolling Interest (USD) | - | 107.00M | 66.00M | 54.00M | 58.00M | 35.00M | 37.00M | 49.00M | 58.00M | 69.00M | 90.00M | 96.00M | 114.00M | - | - |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.99B | 2.44B |
| Noncurrent Liabilities (USD) | 59.70B | 57.69B | 57.75B | 64.13B | 69.04B | 70.26B | 80.26B | - | - | - | - | - | - | - | - |
| Other Current Liabilities (USD) | 45.68B | 40.16B | 33.45B | 36.92B | 30.54B | 35.05B | 27.53B | - | - | - | - | - | - | - | - |
| Accounts Payable (USD) | 10.66B | 8.55B | 7.78B | 6.66B | 5.48B | 5.09B | 4.37B | - | - | - | - | - | - | - | - |
| Current Liabilities (USD) | 56.34B | 48.72B | 41.23B | 43.57B | 36.02B | 40.14B | 31.90B | 47.97B | 45.58B | 44.98B | 45.02B | 43.66B | 43.85B | 42.70B | 37.58B |
| Liabilities (USD) | 116.05B | 106.41B | 98.98B | 107.71B | 105.07B | 110.40B | 112.15B | 47.97B | 45.58B | 44.98B | 45.02B | 43.66B | 43.85B | 42.70B | 37.58B |
| Other Non-current Assets (USD) | 77.89B | 84.55B | 77.55B | 80.96B | 88.27B | 84.95B | 89.23B | - | - | - | - | - | - | - | - |
| Intangible Assets (USD) | 28.56B | 30.86B | 32.49B | 34.10B | 35.18B | 36.56B | 39.00B | - | - | - | - | - | - | - | - |
| Fixed Assets (USD) | 3.65B | - | 3.77B | 3.69B | 4.21B | 4.42B | 4.56B | 1.56B | 1.54B | 1.53B | 1.50B | 1.46B | 1.12B | 1.02B | 862.00M |
| Noncurrent Assets (USD) | 110.11B | 115.41B | 113.81B | 118.76B | 127.65B | 125.93B | 132.80B | - | - | - | - | - | - | - | - |
| Other Current Assets (USD) | 11.71B | 13.98B | 8.13B | 17.34B | 12.44B | 16.47B | 7.14B | - | - | - | - | - | - | - | - |
| Inventory (USD) | 7.34B | 5.65B | 4.78B | 3.72B | 3.17B | 2.66B | 2.82B | - | - | - | - | - | - | - | - |
| Accounts Receivable (USD) | 28.77B | 17.72B | 17.22B | 15.07B | 12.19B | 10.72B | 10.47B | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 47.81B | 37.35B | 30.12B | 36.13B | 27.80B | 29.85B | 20.43B | 61.75B | 59.36B | 57.09B | 55.90B | 54.34B | 53.73B | 51.05B | 43.01B |
| Assets (USD) | 157.92B | 152.76B | 143.93B | 154.89B | 155.45B | 155.77B | 153.23B | 61.75B | 59.36B | 57.09B | 55.90B | 54.34B | 53.73B | 51.05B | 43.01B |
Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.
Ushur announced Voice-Guided Experience, a new capability that enables organizations in regulated industries to guide customers through complex workflows using synchronized voice and mobile interactions. The AI-powered feature keeps voice conversations active while opening a synchronized mobile experience, allowing customers to speak or tap without switching channels. The platform supports 74 languages, maintains enterprise-grade compliance (HITRUST r2, SOC 2, HIPAA), and is designed to improve completion rates and reduce operational burden for healthcare, insurance, and financial services organizations.
The global dental insurance market is projected to grow from USD 118.77 billion in 2026 to USD 198.31 billion by 2032, with a CAGR of 8.72%. Growth is driven by digital transformation, evolving care models, and regulatory shifts. Key trends include provider consolidation, value-based care models, and increased investment in analytics and digital-first distribution channels.
The FTC finalized a settlement with Cigna's Express Scripts pharmacy benefit manager to reduce anticompetitive practices and lower insulin costs by up to $7 billion over the next decade. Cigna reported strong Q4 2025 earnings, beating revenue and EPS estimates, and increased its quarterly dividend to $1.56 per share. The stock rose 3.53% following the announcement.
In Q4 2025 earnings, KKR exceeded revenue expectations at $5.74B but missed on EPS. Cummins beat revenue at $8.5B but fell short on EPS due to Electrolyzer business charges, though it projects 3-8% revenue growth for 2026. Cigna Group outperformed on both revenue ($72.47B) and EPS ($8.08), reflecting strong operational performance.
The FTC has secured a landmark settlement with Cigna's Express Scripts requiring elimination of spread pricing, decoupling rebates from drug list prices, relocating its GPO from Switzerland to the U.S., and adopting a cost-plus reimbursement model for independent pharmacies starting in 2027. The NCPA views this as a major victory against anticompetitive PBM practices that have artificially inflated drug prices and harmed independent pharmacies.
The FTC has paused its administrative case against major pharmacy benefit managers (PBMs) including Cigna, CVS Health, and UnitedHealth Group, suggesting settlement negotiations may be underway. The 14-day suspension delays the evidentiary hearing to July 1. The case, filed in September 2024, accuses PBMs of unfair practices that inflated insulin prices. Recent investigations and political pressure from the Trump administration have intensified scrutiny on PBM practices, particularly regarding markups on specialty drugs and alleged use of shell companies to obscure profits.
UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.
A new report from Hunterbrook Media alleges that CVS Health, UnitedHealth Group, and Cigna are using shell subsidiary companies called GPOs (Group Purchasing Organizations) to hide billions of dollars in drug rebates that should be passed to patients. The report claims these companies collect massive fees through their GPOs while telling customers they've passed on 100% of rebates, effectively siphoning off drug discounts meant for patients. Hunterbrook visited the GPO headquarters in Ireland, Switzerland, and Minnesota, finding mostly empty offices despite handling tens of billions in revenue.
BofA Securities highlighted Cigna's strong potential in commercial health insurance, noting its pharmacy benefit management platform and ability to deliver 10-15% annual EPS growth, while also discussing challenges and opportunities in the healthcare insurance market.
